Market News & Trends
PromoCell Receives EXCiPACT Certification as Manufacturer of Pharmaceutical Excipients to GMP Standards
PromoCell, one of the leading European manufacturers of human cell culture and cell biology products, has recently announced to have successfully completed a comprehensive EXCiPACT…
Vaxart Announces Additional Preclinical COVID-19 Oral Vaccine Data & Publication
Vaxart, Inc. recently announced additional results from its SARS-CoV-2 Hamster Challenge Study, as well as a peer-reviewed publication in Nature Medicine resulting from a collaboration…
Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the US
Entasis Therapeutics Holdings Inc. recently announced the availability of an expanded access program (EAP) for sulbactam-durlobactam or SUL-DUR, an investigational drug, for US patients with…
DURECT Corporation Announces First Patient Dosed in Phase 2b AHFIRM Study
DURECT Corporation recently announced it has dosed the first patient in its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to evaluate the safety and efficacy of DUR-928…
Antios Therapeutics Completes Phase 1b Clinical Trial of Active Site Polymerase Inhibitor Nucleotide
Antios Therapeutics, Inc. recently announced it has completed the Phase 1b clinical trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in patients with…
Ajinomoto Bio-Pharma Services & Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational COVID-19 Therapeutic
Ajinomoto Bio-Pharma Services and Humanigen, Inc. recently announced the companies will be expanding their manufacturing agreement for the fill finish supply of lenzilumab, which is…
Cognate BioServices & Its Gene Therapy Division Cobra Biologics Announce Major Expansion
Cobra Biologics, the gene therapy division of the Cognate BioServices’ group, recently announced a multi-phase augmentation of its plasmid DNA services as a continuation of…
Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck Under Exclusive Worldwide License & Collaboration Agreement
Cocrystal Pharma, Inc. recently announced it has completed all research obligations under the Merck exclusive worldwide license and collaboration agreement, and that Merck is now…
Neuropathix Announces Publication of Its Global PCT Patent for a Novel Hops-Inspired Neuroprotectant
Neuropathix, Inc. recently announced the publication of its global WIPO/PCT Patent WO 2020/ 264324 – Use of Certain Phosphatidylcholines Containing Long Chain Polyunsaturated Fatty Acids…
Quantum Genomics Launches Phase 3 Pivotal REFRESH Study
Quantum Genomics recently announced the launch of its Phase 3 REFRESH study in difficult-to-treat or resistant hypertension. This new study is part of firibastat’s Phase…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….